{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-031918","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.196197+00:00","generated_at":"2026-06-05T01:40:08.658650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024","bullets":["Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.","GAAP gross margin 45%; adjusted gross margin 58%; net loss $37.7M vs $32.9M.","Adjusted EBITDA loss improved to $14.6M from $22.9M.","Cash $19.3M as of Dec 31, 2023; proceeds $14.6M from orthobiologics divestiture.","FDA 510(k) decision for CanGarooRM expected in first half 2024; no additional data requested."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-031918","json":"https://secwatch.observer/filing/0001104659-24-031918.json","markdown":"https://secwatch.observer/filing/0001104659-24-031918.md","text":"https://secwatch.observer/filing/0001104659-24-031918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924031918/0001104659-24-031918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924031918/tm248252d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:40:08.658650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2c7fd07148d29dd8d221a56ccc69fc48489ea0c","claim":"ELUTIA INC. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924031918/0001104659-24-031918-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}